Go offline with the Player FM app!
The Path to Healthy Aging: Pioneering Therapies for Age-Related Diseases with Rejuvenate Biomed's Ann Beliën
Manage episode 470932247 series 2900042
In this episode, Vera spoke with Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, a biotech company leveraging AI-driven platforms to develop therapies for age-related diseases and promote healthy aging.
Rejuvenate Biomed is aiming to transform the treatment landscape for diseases such as sarcopenia, neuromuscular, metabolic and neurodegenerative disorders. Dr. Beliën founded Rejuvenate Biomed in 2017 and under her leadership, it transitioned from a discovery start-up to a clinical-stage biotech company.
Dr. Beliën has more than two decades of experience in drug development that has included international assignments in the US, the Netherlands and Belgium in various therapeutic areas, including oncology, neurology, immunology and infectious diseases.
Prior to founding Rejuvenate Biomed, Dr. Beliën served as a due diligence representative for R&D at Johnson & Johnson (J&J) where she was also a member of the management board of Janssen Prevention Center for five years.
Dr. Beliën holds a PhD from the University of Irchel in Zürich, Switzerland and a master’s degree from the Free University of Brussels (VUB), Belgium.
To hear more about how Rejuvenate Biomed is pioneering therapies for age-related diseases and working to promote healthy aging.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
204 episodes
Manage episode 470932247 series 2900042
In this episode, Vera spoke with Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, a biotech company leveraging AI-driven platforms to develop therapies for age-related diseases and promote healthy aging.
Rejuvenate Biomed is aiming to transform the treatment landscape for diseases such as sarcopenia, neuromuscular, metabolic and neurodegenerative disorders. Dr. Beliën founded Rejuvenate Biomed in 2017 and under her leadership, it transitioned from a discovery start-up to a clinical-stage biotech company.
Dr. Beliën has more than two decades of experience in drug development that has included international assignments in the US, the Netherlands and Belgium in various therapeutic areas, including oncology, neurology, immunology and infectious diseases.
Prior to founding Rejuvenate Biomed, Dr. Beliën served as a due diligence representative for R&D at Johnson & Johnson (J&J) where she was also a member of the management board of Janssen Prevention Center for five years.
Dr. Beliën holds a PhD from the University of Irchel in Zürich, Switzerland and a master’s degree from the Free University of Brussels (VUB), Belgium.
To hear more about how Rejuvenate Biomed is pioneering therapies for age-related diseases and working to promote healthy aging.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
204 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.